Dossier assessment
Nusinersen (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Nusinersen (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Nusinersen (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Patients with 5q spinal muscular atrophy (SMA)
Early onset of disease (infantile form, type 1): indication of major added benefit. Later onset of disease (type 2, type 3 and type 4): added benefit not proven. Pre-symptomatic patients: hint of non-quantifiable added benefit.
Press releases
Nusinersen in SMA: indication of major added benefit in children with early-onset disease
Additional information
Federal Joint Committee (G-BA)
2021.05.20 A G-BA decision was published.
Project details
- Project no.
- A20-114
- Commission
- Commission awarded on 02.12.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Nusinersen (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Addendum
Nusinersen (spinal muscular atrophy) - Addendum to Commission A20-114
Status: Commission completed